Investment Thesis

AbbVie Inc. (ABBV) is a BUY at the current price of $224.95, as the market is underestimating the company's long-term growth potential driven by its robust pipeline and established product portfolio. Despite facing patent expirations for HUMIRA, AbbVie has positioned itself well with innovative therapies like SKYRIZI and RINVOQ, which are gaining traction in their respective markets. The current valuation does not reflect the strength of its therapeutic offerings and expected revenue growth, particularly as the company transitions to a broader immunology portfolio.

Competitive Moat

characterized by its intangible assets, particularly its proprietary drug formulations and established brand reputation. The company's extensive investment in R&D has produced a portfolio of drugs that are difficult for competitors to replicate, ensuring a degree of pricing power in its primary markets. This advantage is expected to endure over the next 5-10 years, though threats from biosimilars and emerging biotech firms, particularly in the immunology and oncology spaces, could challenge market share and pricing dynamics.

Growth Engine

Future revenue growth for AbbVie is anticipated to stem primarily from its innovative therapies in immunology and oncology, with a total addressable market (TAM) continuing to expand due to rising incidences of autoimmune diseases and cancers. The company is seeing positive market uptake for SKYRIZI and RINVOQ, which are positioned to replace HUMIRA in several indications. Additionally, geographic expansion into emerging markets offers further organic growth opportunities. AbbVie is currently gaining market share against competitors, bolstered by its strong clinical data and patient adherence.